These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. In vivo evaluation of the CB Mustafa M; Donvito G; Moncayo L; Swafford A; Poklis J; Grauer R; Olszewska T; Ignatowska-Jankowska B; Kendall DA; Lu D; Lichtman AH Pharmacol Biochem Behav; 2020 Mar; 190():172840. PubMed ID: 31899221 [TBL] [Abstract][Full Text] [Related]
3. The great divide: Separation between in vitro and in vivo effects of PSNCBAM-based CB Gamage TF; Farquhar CE; Lefever TW; Thomas BF; Nguyen T; Zhang Y; Wiley JL Neuropharmacology; 2017 Oct; 125():365-375. PubMed ID: 28803965 [TBL] [Abstract][Full Text] [Related]
4. A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects. Ignatowska-Jankowska BM; Baillie GL; Kinsey S; Crowe M; Ghosh S; Owens RA; Damaj IM; Poklis J; Wiley JL; Zanda M; Zanato C; Greig IR; Lichtman AH; Ross RA Neuropsychopharmacology; 2015 Dec; 40(13):2948-59. PubMed ID: 26052038 [TBL] [Abstract][Full Text] [Related]
5. Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling. Shore DM; Baillie GL; Hurst DH; Navas F; Seltzman HH; Marcu JP; Abood ME; Ross RA; Reggio PH J Biol Chem; 2014 Feb; 289(9):5828-45. PubMed ID: 24366865 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB Owens RA; Mustafa MA; Ignatowska-Jankowska BM; Damaj MI; Beardsley PM; Wiley JL; Niphakis MJ; Cravatt BF; Lichtman AH Neuropharmacology; 2017 Oct; 125():80-86. PubMed ID: 28673548 [TBL] [Abstract][Full Text] [Related]
7. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. Ahn KH; Mahmoud MM; Kendall DA J Biol Chem; 2012 Apr; 287(15):12070-82. PubMed ID: 22343625 [TBL] [Abstract][Full Text] [Related]
15. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Tham M; Yilmaz O; Alaverdashvili M; Kelly MEM; Denovan-Wright EM; Laprairie RB Br J Pharmacol; 2019 May; 176(10):1455-1469. PubMed ID: 29981240 [TBL] [Abstract][Full Text] [Related]
16. Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor. Khajehali E; Malone DT; Glass M; Sexton PM; Christopoulos A; Leach K Mol Pharmacol; 2015 Aug; 88(2):368-79. PubMed ID: 26044547 [TBL] [Abstract][Full Text] [Related]
18. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice. McMahon LR; Koek W Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486 [TBL] [Abstract][Full Text] [Related]
19. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism. Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649 [TBL] [Abstract][Full Text] [Related]
20. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons. Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]